SQZ Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2023-04-26 | 2021 | Micah Zajic Former Chief Financial Officer | 377,400 | 0 | 0 | 0 | 8,020 | 758,795 |
| 2023-04-26 | 2022 | Micah Zajic Former Chief Financial Officer | 405,404 | 0 | 0 | 0 | 170,983 | 1,004,267 |
| 2023-04-26 | 2021 | Lawrence Knopf General Counsel | 345,100 | 0 | 0 | 0 | 8,700 | 1,005,693 |
| 2023-04-26 | 2022 | Lawrence Knopf General Counsel | 395,238 | 0 | 0 | 0 | 5,423 | 944,031 |
| 2023-04-26 | 2021 | Marshelle Smith Warren, M.D. Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-26 | 2022 | Marshelle Smith Warren, M.D. Chief Medical Officer | 235,699 | 0 | 0 | 0 | 4,150 | 775,977 |
| 2023-04-26 | 2021 | Armon Sharei, Ph.D. Former Chief Executive Officer | 520,200 | 0 | 0 | 0 | 8,020 | 2,901,460 |
| 2023-04-26 | 2022 | Armon Sharei, Ph.D. Former Chief Executive Officer | 550,000 | 0 | 0 | 0 | 47,960 | 2,704,474 |
| 2023-04-26 | 2022 | Howard Bernstein, M.D., Ph.D. Interim Chief Executive Officer | 400,227 | 0 | 0 | 0 | 151,910 | 1,624,513 |
| 2023-04-26 | 2021 | Howard Bernstein, M.D., Ph.D. Interim Chief Executive Officer | 391,400 | 0 | 0 | 0 | 6,389 | 1,346,234 |
| 2022-04-26 | 2021 | Armon Sharei, Ph.D. Chief Executive Officer | 520,200 | 0 | 0 | 234,090 | 8,020 | 2,901,460 |
| 2022-04-26 | 2020 | Armon Sharei, Ph.D. Chief Executive Officer | 467,313 | 0 | 0 | 218,251 | 7,005 | 2,324,143 |
| 2022-04-26 | 2021 | Teri Loxam Chief Financial Officer | 380,042 | 0 | 0 | 0 | 199,537 | 1,893,027 |
| 2022-04-26 | 2020 | Teri Loxam Chief Financial Officer | 400,000 | 0 | 0 | 156,800 | 76,228 | 772,803 |
| 2022-04-26 | 2021 | Howard Bernstein, M.D., Ph.D. Chief Scientific Officer | 391,400 | 0 | 0 | 148,732 | 6,389 | 1,346,234 |
| 2022-04-26 | 2020 | Howard Bernstein, M.D., Ph.D. Chief Scientific Officer | 357,080 | 0 | 0 | 148,960 | 4,564 | 750,214 |
| 2022-04-26 | 2021 | Oliver Rosen, M.D. Chief Medical Officer | 293,427 | 0 | 0 | 0 | 8,700 | 1,191,248 |
| 2022-04-26 | 2020 | Oliver Rosen, M.D. Chief Medical Officer | 400,722 | 0 | 0 | 148,019 | 8,550 | 1,059,625 |
| 2022-04-26 | 2021 | Lawrence Knopf General Counsel | 345,100 | 0 | 0 | 124,236 | 8,700 | 1,005,693 |
| 2022-04-26 | 2020 | Lawrence Knopf General Counsel | 334,583 | 0 | 0 | 131,320 | 8,550 | 1,406,853 |
| 2021-04-26 | 2020 | Micah Zajic Chief Business Officer | 93,212 | 50,000 | 0 | 142,140 | 3,300 | 2,002,095 |
| 2021-04-26 | 2020 | Lawrence Knopf General Counsel | 334,583 | 0 | 0 | 131,320 | 8,550 | 1,406,853 |
| 2021-04-26 | 2019 | Oliver Rosen, M.D. Chief Medical Officer | 388,750 | 175,000 | 0 | 122,400 | 2,209 | 1,437,341 |
| 2021-04-26 | 2020 | Oliver Rosen, M.D. Chief Medical Officer | 400,722 | 0 | 0 | 148,019 | 8,550 | 1,059,625 |
| 2021-04-26 | 2019 | Teri Loxam Chief Financial Officer | 130,513 | 125,000 | 0 | 140,000 | 35,006 | 1,807,323 |
| 2021-04-26 | 2020 | Teri Loxam Chief Financial Officer | 400,000 | 0 | 0 | 156,800 | 76,228 | 772,803 |
| 2021-04-26 | 2019 | Armon Sharei, Ph.D. Chief Executive Officer | 455,000 | 0 | 0 | 176,000 | 3,270 | 1,001,470 |
| 2021-04-26 | 2020 | Armon Sharei, Ph.D. Chief Executive Officer | 467,313 | 0 | 0 | 218,251 | 7,005 | 2,324,143 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
